ReviewCurrent problems in cardiology2020
Lean Mass Abnormalities in Heart Failure: The Role of Sarcopenia, Sarcopenic Obesity, and Cachexia.
Review in Current problems in cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 6 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Differences in peak oxygen uptake in heart failure patients with and without cachexia: A systematic review and meta-analysis.Physiological reports · 2025Pooled it
- Comparing exercise modalities during caloric restriction: a systematic review and network meta-analysis on body composition.Frontiers in nutrition · 2025Pooled it
- Effects of Different Exercises Combined with Different Dietary Interventions on Body Composition: A Systematic Review and Network Meta-Analysis.Nutrients · 2024Pooled it
- Sarcopenia Predicts Adverse Prognosis in Patients with Heart Failure: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2023Pooled it
- A systematic review and meta-analysis of the association between sarcopenia and myocardial infarction.BMC geriatrics · 2023Pooled it
- The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis.Frontiers in physiology · 2022Pooled it
- A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2023Trial
- The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.Diabetes/metabolism research and reviews · 2020Trial
- Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.Endocrinology, diabetes & metabolism · 2026Review
- GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives.Nutrients · 2026Review
- Phase Angle Shows a Negative Correlation With Serum GDF-15 Concentrations in Hospitalized Patients With Cardiovascular Disease.Journal of nutrition and metabolism · 2026Article
- Systemic energy metabolism changes in patients with heart failure receiving specific oral nutritional supplements in combination with Mediterranean diet.Frontiers in nutrition · 2026Article
- The role of fat-free mass index in evaluating protein-energy wasting in maintenance hemodialysis patients: a multicenter cross-sectional study.Frontiers in nutrition · 2026Article
- Fostering interconnected care in heart failure: a call to action for a comprehensive assessment and management of the patient's journey.Internal and emergency medicine · 2025Review
- Body composition in patients with obesity-related heart failure with preserved ejection fraction: A comparison study.JPEN. Journal of parenteral and enteral nutrition · 2025Article
- Integrated transcriptomics unveils mitochondrial oxidative phosphorylation dysfunction as a shared mechanism in sarcopenia and obesity.Scientific reports · 2025Article
- GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.JAMA network open · 2025Article
- Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation.European journal of clinical investigation · 2025Review
- Beyond body mass index: the role of muscle strength in reducing mortality risk in older adults with severe obesity - multi-country cohort study.European journal of clinical nutrition · 2025Article
- Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.European journal of heart failure · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The role of body composition in patients with heart failure (HF) has been receiving much attention in the last few years. Particularly, reduced lean mass (LM), the best surrogate for skeletal muscle mass, is independently associated with abnormal cardiorespiratory fitness (CRF) and muscle strength, ultimately leading to reduced quality of life and worse prognosis. While in the past, reduced CRF in patients with HF was thought to result exclusively from cardiac dysfunction leading to reduced cardiac output at peak exercise, current evidence supports the concept that abnormalities in LM may also play a critical role. Abnormalities in the LM body composition compartment are associated with the development of sarcopenia, sarcopenic obesity, and cachexia. Such conditions have been implicated in the pathophysiology and progression of HF. However, identification of such conditions remains challenging, as universal definitions for sarcopenia, sarcopenic obesity, and cachexia are lacking. In this review article, we describe the most common body composition abnormalities related to the LM compartment, including skeletal and respiratory muscle mass abnormalities, and the consequences of such anomalies on CRF and muscle strength in patients with HF. Finally, we discuss the potential nonpharmacologic therapeutic strategies such as exercise training (ie, aerobic exercise and resistance exercise) and dietary interventions (ie, dietary supplementation and dietary patterns) that have been implemented to target body composition, with a focus on HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.